Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 105120, 12 pages
http://dx.doi.org/10.1155/2014/105120
Research Article

Diethylcarbamazine Attenuates the Development of Carrageenan-Induced Lung Injury in Mice

1Pós-Graduação em Ciências Biológicas da Universidade Federal de Pernambuco, Avenida Professor Moraes Rego, s/n, Cidade Universitária, 50670-901 Recife, PE, Brazil
2Instituto Aggeu Magalhães, FIOCRUZ, Avenida Professor Moraes Rego, s/n, Cidade Universitária, 50670-420 Recife, PE, Brazil
3Departamento de Morfologia e Fisiologia Animal da Universidade Federal Rural de Pernambuco, Rua Dom Manoel de Medeiros, s/n, Dois Irmãos, 52171-900 Recife, PE, Brazil
4Laboratório de Ultraestrutura, Instituto Aggeu Magalhães, FIOCRUZ, Avenida Professor Moraes Rego, s/n, Cidade Universitária, 50670-420 Recife, PE, Brazil

Received 19 July 2013; Accepted 3 December 2013; Published 16 January 2014

Academic Editor: Tânia Fröde

Copyright © 2014 Edlene Lima Ribeiro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Diethylcarbamazine (DEC) is an antifilarial drug with potent anti-inflammatory properties as a result of its interference with the metabolism of arachidonic acid. The aim of the present study was to evaluate the anti-inflammatory activity of DEC in a mouse model of acute inflammation (carrageenan-induced pleurisy). The injection of carrageenan into the pleural cavity induced the accumulation of fluid containing a large number of polymorphonuclear cells (PMNs) as well as infiltration of PMNs in lung tissues and increased production of nitrite and tumor necrosis factor-α and increased expression of interleukin-1β, cyclooxygenase (COX-2), and inducible nitric oxide synthase. Carrageenan also induced the expression of nuclear factor-κB. The oral administration of DEC (50 mg/Kg) three days prior to the carrageenan challenge led to a significant reduction in all inflammation markers. The present findings demonstrate that DEC is a potential drug for the treatment of acute lung inflammation.